Skip to main content
. 2021 Jan 11;14(1):1–7. doi: 10.1159/000508068

Fig. 3.

Fig. 3

Chest computed tomography scans. A–C Performed on day 468 after the initiation of pembrolizumab. D–F Performed on day 964 after the initiation of pembrolizumab. There was no recurrence of lung adenocarcinoma, and the patient maintained a complete response.